Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib
Open Access
- 18 November 2020
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 124 (1) , 176-182
Abstract
Background: Treatment strategies inhibiting BRAF in combination with EGFR have been developed in patients with BRAFV600E mutant metastatic colorectal cancer, but intrinsic and secondary resistance remains a challenge. We aimed to investigate which genetic alterations cause intrinsic non-response and/or acquired resistance in these patients receiving therapies consisting of a backbone of BRAF and EGFR inhibition. Methods: This was a cohort study on genetic alterations in patients with BRAFV600E mutant advanced colorectal cancer treated with inhibitors of the MAPK pathway. We examined tumour tissue for genetic alterations at baseline, during treatment and at progression. Results: In total, 37 patients were included in this cohort. Genetic alterations in EGFR and in PIK3CA are associated with non-response. A greater fraction of non-responders (75%) versus responders (46%) had at least one genetic alteration in other genes than TP53, APC or BRAF. Secondary resistance mutations (n = 16 patients) were observed most frequently in the PI3K pathway (n = 6) and in receptor tyrosine kinases (n = 4), leading to increased upstream signalling. Conclusions: Genetic alterations in the PI3K and upstream receptor tyrosine kinases were mostly associated with intrinsic and acquired resistance. By understanding these alterations, simultaneous or alternating treatments with targeted inhibitors might improve response duration.Keywords
This publication has 25 references indexed in Scilit:
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal CancerJournal of Clinical Oncology, 2015
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal CancerJournal of Clinical Oncology, 2015
- Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAFOncogene, 2015
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway AlterationsCancer Discovery, 2015
- Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer PatientsClinical Cancer Research, 2015
- Molecular mechanisms of epithelial–mesenchymal transitionNature Reviews Molecular Cell Biology, 2014
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with VemurafenibCancer Discovery, 2012
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFRNature, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Mutations of the BRAF gene in human cancerNature, 2002